Skip to main content

Table 2 Biologics as first-line and subsequently, and concomitant therapy in patients with juvenile idiopathic arthritis

From: Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

Drug First-line Second-line or later Total
Etanercept 204 (43.5) 119 (25.8) 323 (34.7)
Infliximab 143 (30.5) 58 (12.6) 201 (21.6)
Adalimumab 89 (19.0) 108 (23.4) 197 (21.2)
Anakinra 8 (1.7) 15 (3.3) 23 (2.5)
Rituximab 0 (0.0) 72 (15.6) 72 (7.7)
Abatacept 5 (1.1) 28 (6.1) 33 (3.6)
Tocilizumab 16 (3.4) 40 (8.7) 56 (6.0)
Golimumab 2 (0.4) 13 (2.8) 15 (1.6)
Certolizumab 2 (0.4) 5 (1.1) 7 (0.8)
Canakinumab 0 (0.0) 2 (0.4) 2 (0.2)
Ustekinumab 0 (0.0) 1 (0.2) 1 (0.1)
Use of concomitant drugs
 - Monotherapy 177 (37.7) 217 (47.1) 394 (42.4)
 - Methotrexate 225 (48.0) 184 (39.9) 409 (44.0)
 - Glucocorticoids 155 (33.1) 145 (31.5) 300 (32.3)
 - Leflunomide 29 (6.2) 26 (5.7) 55 (5.9)
 - Sulfasalazine 26 (5.5) 13 (2.8) 39 (4.2)
 - Gold salts 1 (0.2) 1 (0.1)
 - Azathioprine 3 (0.6) 5 (1.1) 8 (0.9)
 - Hydroxychloroquine 4 (0.9) 5 (1.1) 9 (1.0)
  1. Data are expressed as number of patients (%)